Colorectal Cancer

Pashtoon M. Kasi, MD, MBBS, MS, discusses the patient populations with colorectal cancer that are likely to benefit from immunotherapy treatment.

Wells A. Messersmith, MD, reviews key updates to the NCCN guidelines for the treatment of colorectal cancer.

The combination of FOLFOXIRI plus molecular targeted therapies, including bevacizumab, was effective as a first-line treatment in metastatic colorectal cancer, according to findings from a retrospective study recently published in <em>Oncotarget.</em>

The clinical practice guidelines for the treatment of patients with colorectal cancer have been updated by NCCN to include the combination of&nbsp;encorafenib plus binimetinib in addition to EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with <em>BRAF</em> V600E&ndash;mutant metastatic CRC, after 1 or 2 prior therapies for metastatic disease.

The healthcare community is still awaiting a response from the Centers for Medicare &amp; Medicaid Services to the opposition of the agency&rsquo;s proposal to substantially revise the Medicare Part D protected drug classes.

Optimal Treatment of Chemoresistant mCRC

Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results&ndash;Medicare linked database.

In an interview with <em>Targeted Therapies in Oncology</em>, Michael Cusnir, MD, explained that Y-90 is a type of beta emitter that is extremely focused, which allows for the treatment to be localized without affecting healthy portions of the liver or other structures surrounding the liver; it is delivered to selectively embolize the liver.

The majority of younger patients ultimately diagnosed with colorectal cancer waited 3 to 12 months to see a doctor after symptoms began and were commonly misdiagnosed with&nbsp;issues such as hemorrhoids, irritable bowel syndrome, and anemia, according to recent findings.

A 75-Year-Old Man With Right-Sided mCRC